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Abstract APO2L (TRAIL) is a novel CD95L (Fas/APO-1-L)
homologous cytotoxic cytokine that interacts with various
receptors which transmit (DR4, DR5) or inhibit (DcR1, DcR2)
an apoptotic signal. Here, we report that human glioma cell lines
preferentially express mRNAs for agonistic death receptors DR4
(8/12) and DR5 (11/12) rather than the death-inhibitory decoy
receptors DcR1 (4/12) and DcR2 (2/12). Ten of 12 cell lines are
susceptible to APO2L-induced apoptosis. The resistant cell lines,
U138MG and U373MG, are cross-resistant to CD95L-induced
apoptosis. Similar to CD95L-induced apoptosis, APO2L-in-
duced apoptosis is inhibited by ectopic expression of the caspase
inhibitor, crm-A, or of bcl-2, or by coexposure to the
corticosteroid, dexamethasone, or the lipoxygenase inhibitor,
nordihydroguaretic acid. There is no correlation between p53
genetic status of the cell lines and their susceptibility to APO2L-
induced apoptosis, but the latter is moderately enhanced by
ectopic expression of wild-type p53. APO2L targeting may be a
promising approach for selectively targeting apoptosis to human
malignant glioma cells.
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1. Introduction
Targeting the tumor necrosis factor (TNF) receptor family
member, CD95 (Fas/APO-1), by agonistic CD95 antibodies or
the natural ligand, CD95 ligand (CD95L), is a promising
therapeutic strategy for malignant glioma [1,2]. The APO2
ligand (APO2L), also referred to as TNF-related apoptosis-
inducing ligand (TRAIL), is a novel member of the TNF
cytokine family [3,4]. APO2L mRNA is expressed in most
human tissues, including spleen, lung, and prostate, but not
brain. APO2L is a potent inducer of apoptosis in di¡erent
cancer cell lines. The ¢rst APO2L receptor to be cloned,
DR4, showed sequence homology to the TNF receptor and
to CD95 [5]. An additional APO2L receptor, DR5, also me-
diates APO2L-induced apoptosis [6,7]. Similar to CD95-medi-
ated apoptosis, APO2L-induced apoptosis involves caspase
activation [5^11]. Although DR4 is expressed in many human
tissues including spleen and peripheral blood leukocytes,
APO2L induces apoptosis in transformed cells but not in un-
stimulated primary T cells [10]. This can be explained by the
co-expression of an antagonistic receptor, decoy receptor 1
(DcR1) or TRID (TRAIL receptor without intracellular do-
main), which is found in normal cells but is absent in most
cancer cell lines [6,7]. Identi¢cation of another inhibitory re-
ceptor, DcR2 [12] or TRAIL-R4 [13], adds further complexity
to the regulation of the APO2L/APO2L receptor system. In
contrast to injection of CD95 antibodies and CD95L which is
lethal to mice [14], injection of human APO2L is well-toler-
ated in mice (Ashkenazi, unpublished), suggesting that
APO2L might be a relatively safe agent for cancer therapy.
The present study examines the expression of APO2L recep-
tors in human glioma cells and their susceptibility to APO2L-
induced apoptosis.
2. Materials and methods
2.1. Materials and cell culture
APO2L was prepared as described [3]. Dexamethasone, NDGA and
CHX were purchased from Sigma (Deisenhofen, Germany). T98G
human malignant glioma cells were obtained from the American
Type Culture Collection (Rockville, MD). A172, LN-229, LN-18,
LN-308, LN-319, LN-428, U87MG, U138MG, U251MG, U373MG
and D247MG human malignant glioma cells were kindly provided by
Dr. N. de Tribolet (Lausanne, Switzerland). The glioma cells were
cultured in DMEM containing 10% FCS, 2 mM glutamine, and 1%
penicillin/streptomycin [1]. Soluble CD95L was derived from the
supernatant of CD95L cDNA-transfected N2A murine neuroblasto-
ma cells [15]. The amount of supernatant CD95L diluted in 100 Wl
medium that was necessary to kill 50% of LN-18 cells within 24 h was
de¢ned as one unit of CD95L.
Human glioma cell lines engineered to express murine bcl-2 or
murine p53 Val135 and the respective neo or hygro control cell lines
have been described [16,17]. A crm-A expression plasmid and puro
control vector were obtained from Dr. A. Strasser [18]. All transfec-
tions were carried out using electroporation (Bio-Rad Gene Pulser,
250 V, 950 WF). Selection was done with G418 (neo, 0.5 mg/ml),
hygromycin B (hygro, 200 Wg/ml) or puromycin (puro, 2 Wg/ml). Ex-
pression of the transgenes was ascertained by immunoblot analysis
(bcl-2, p53) or Northern blot analysis (crm-A) (data not shown).
2.2. Survival and apoptosis assays
10 000 cells per well were seeded and treated as described, and
survival was assessed by crystal violet staining in 96 well plates [1].
The experimental procedures for in situ DNA end labeling and quan-
ti¢cation of DNA fragmentation have been published in detail else-
where [19].
2.3. RT-PCR
Total RNA was isolated by guanidinium thiocyanate-phenol-
chloroform extraction and treated with RNase-free DNase I (10 U/
ml) for 30 min at 25‡C to remove genomic DNA contamination.
cDNA was synthesized from 5 mg RNA in a ¢nal volume of 20 Wl
using SuperScript II (Gibco-BRL, Gaithersburg, MD, USA) and oli-
go dT priming (Pharmacia, Uppsala, Sweden). The PCR conditions
were as follows: DR4 35 cycles, 45 s/95‡C, 45 s/60‡C, 45 s/72‡C,
primer sequences CGATGTGGTCAGAGCTGGTACAGC (nucleo-
tides 1182^1205) and GGACACGGCAGAGCCTGTGCCATC (nu-
cleotides 1375^1398); DR5 35 cycles, 45 s/95‡C, 45 s/60‡C, 45 s/72‡C,
primer sequences GGGAGCCGCTCATGAGGAAGTTGG (nucleo-
tides 1113^1136) and GGCAAGTCTCTCTCCCAGCGTCTC (nu-
cleotides 1241^1264); DcR1 35 cycles, 45 s/95‡C, 45 s/59‡C, 45 s/
72‡C, primer sequences GTTTGTTTGAAAGACTTCACTGTG (nu-
cleotides 963^986) and GCAGGCGTTTCTGTCTGTGGGAAC (nu-
cleotides 1079^1102); DcR2 35 cycles, 45 s/95‡C, 45 s/52‡C, 45 s/72‡C,
primer sequences CTTCAGGAAACCAGAGCTTCCCTC (nucleo-
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tides 1330^1353) and TTCTCCCGTTTGCTTATCACACGC (nu-
cleotides 1506^1529); L-actin 35 cycles, 45 s/95‡C, 45 s/55‡C, 45 s/
72‡C, primer sequences TGTTTGAGACCTTCAACACCC (nucleo-
tides 409^429) and AGCACTGTGTTGGCGTACAG (nucleotides
918^937). The PCR fragments were separated in 2% agarose gels
and visualized by ethidium bromide. The L-actin cDNA fragment
was ampli¢ed as an internal control for equal ampli¢cation. A water
control was run in each ampli¢cation to control for cross-contamina-
tion between tubes. No signal was obtained when RT was omitted
during the RT step, con¢rming that the PCR signals were not derived
from genomic DNA contamination.
2.4. Flow cytometry
CD95 expression at the cell surface was measured and quanti¢ed as
SFI indices as outlined [20]. Brie£y, 106 cells were trypsinized, centri-
fuged for 10 min at 4‡C, stained with FITC-labeled anti-CD95 anti-
body (UB2, Immunotech, Hamburg, Germany) or FITC-labeled
mouse IgG1 (1 Wg/ml) as a control, diluted in 100 Wl PBS containing
1% bovine serum albumin and 0.01% sodium azide (£ow cytometry
bu¡er), and incubated for 30 min at 4‡C. Thereafter, antibody was
removed, cells washed twice in £ow cytometry bu¡er, and resus-
pended in 300 Wl PBS containing 1% paraformaldehyde and stored
light-protected at 4‡C until analysis in a FACScalibur (Becton-Dick-
inson, Heidelberg, Germany). CD95 expression is expressed as SFI
(speci¢c £uorescence index; mean £uorescence of speci¢c antibody/
mean £uorescence of isotype antibody).
2.5. Statistical analysis
Correlation analysis of APO2L receptor and CD95 expression was
calculated by ANOVA. Correlation analysis of susceptibility to
CD95L and APO2L was performed using Pearson correlation of sur-
vival fractions. Synergy between APO2L- and CD95L-induced apop-
tosis was assessed using the fractional product method of Webb as
outlined in previous studies [15].
3. Results
3.1. Expression of APO2L receptors in human malignant
glioma cell lines
The expression of DR4, DR5, DcR1 and DcR2 mRNAs
was assessed by RT-PCR analysis (Fig. 1A). DR4 was ex-
pressed in eight of 12 cell lines. DR5 was expressed in all
cell lines except for LN-428. In contrast, the decoy receptors
DcR1 and DcR2 were only expressed in the minority of cell
lines: DcR1 expression was detected in four cell lines (T98G,
LN-319, LN-229, U251MG) whereas DcR2 expression was
detected only in T98G and A172 cells. For comparison,
CD95 protein expression in these cell lines was determined
by £ow cytometry (Fig. 1B). No correlation between the ex-
pression of CD95 and any APO2L receptor became apparent.
For this analysis, the PCR data for APO2L receptor expres-
sion were rated as negative or positive, and related to CD95
expression as SFI data, or CD95 expression ranked high or
low (n = 6 each).
3.2. Glioma cells are susceptible to APO2L-induced
cell death
Next, the glioma cells were exposed to soluble APO2L (Fig.
2). For comparison, the cells were exposed to CD95L, and to
combinations of APO2L and CD95L, in parallel. Further,
these experiments were performed in the absence or presence
of CHX because inhibition of protein synthesis has previously
been shown to sensitize glioma cells to CD95L-induced apop-
tosis [1]. In the absence of CHX, APO2L killed LN-18,
U87MG, LN-428, D247MG, T98G, LN-229, U251MG, LN-
308 and A172 cells rather e⁄ciently whereas U138MG and
U373MG cells were resistant. Coexposure to APO2L and
CHX enhanced APO2L-induced cytotoxicity especially at
lower concentrations of APO2L, e.g. in U87MG, D247MG,
LN-319, LN-229, U251MG, LN-308 and A172 cells.
U138MG and U373MG cells were resistant even in the pres-
ence of CHX. APO2L-induced cell death showed typical fea-
tures of apoptosis such as membrane blebbing and nuclear
condensation as observed by phase contrast microscopy and
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Table 1
APO2L-induced apoptosis of human malignant glioma cells: modulation by bcl-2, crm-A and p53
CHX CD95L APO2L
3 + 3 +
LN-18 neo 70 þ 2 42 þ 3 65 þ 2 30 þ 1
LN-18 bcl-2 92 þ 5* 55 þ 5* 93 þ 3* 40 þ 1*
LN-229 neo 98 þ 3 27 þ 3 75 þ 2 21 þ 4
LN-229 bcl-2 97 þ 7 67 þ 6* 83 þ 6 46 þ 5*
LN-18 puro 65 þ 0 29 þ 2 54 þ 4 34 þ 5
LN-18 crm-A 113 þ 1* 94 þ 7* 124 þ 3* 94 þ 4*
LN-229 puro 82 þ 2 14 þ 2 51 þ 1 9 þ 2
LN-229 crm-A 110 þ 2* 93 þ 3* 108 þ 3* 95 þ 4*
LN-18 hygro, 38.5‡C 49 þ 2 37 þ 3 67 þ 2 46 þ 4
LN-18 p53, 38.5‡C 42 þ 1 29 þ 1* 69 þ 3 31 þ 5*
LN-18 hygro, 32.5‡C 102 þ 5 54 þ 4 76 þ 4 45 þ 3
LN-18, p53, 32.5‡C 91 þ 5 36 þ 3* 50 þ 2* 33 þ 5*
LN-229 hygro, 38.5‡C 89 þ 7 24 þ 2 69 þ 2 22 þ 1
LN-229 p53, 38.5‡C 93 þ 4 13 þ 0* 70 þ 5 15 þ 1*
LN-229 hygro, 32.5‡C 105 þ 10 31 þ 6 64 þ 8 26 þ 1
LN-229 p53, 32.5‡C 91 þ 5 17 þ 2* 40 þ 7* 17 þ 2*
The cells were treated with CD95L (10 U/ml for LN-18, 100 U/ml for LN-229) or APO2L (0.1 Wg/ml for LN-18, 1 Wg/ml for LN-229). Survival
assessed by crystal violet staining at 16 h. For the experiments assessing the role of p53 in wild-type conformation (32.5‡C), the cells were
preincubated for 4 h at 32.5‡C before treatment. Data are expressed as mean percentages of survival and S.D. (n = 3, *P6 0.05, t-test, signi¢cant
di¡erence compared with vector controls).
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DNA breaks on in situ DNA end labeling (data not shown) as
well as quantitative DNA fragmentation (Fig. 3A,B).
No clear relation between APO2L receptor expression at
mRNA level and susceptibility to apoptosis became apparent.
Both resistant cell lines, U373MG and U138MG, expressed
DR5 but not DR4. However, both cell lines did not express
the decoy receptors. On the other hand, expression of either
DR4 or DR5 was su⁄cient to mediate apoptosis in LN-428,
T98G and LN-308 cells.
A comparison of sensitivity to APO2L and CD95L showed
some interesting parallels. Thus, LN-18 was most sensitive to
both cytokines, and CHX did little to enhance cytotoxicity in
these cells. The APO2L-resistant cell lines U138MG and
U373MG were also resistant to CD95L. Survival fractions
after exposure to CD95L (100 U/ml) correlated signi¢cantly
with the survival fractions after exposure to APO2L (1 Wg/ml)
(r = 0.73, P6 0.05). According to the fractional product meth-
od, the coexposure to APO2L and CD95L (Fig. 2) had no
synergistic activity except in A172 cells with the lower cyto-
kine concentrations and in the absence of CHX (79.6% pre-
dicted survival, 59.2% factual survival). To con¢rm that
APO2L does not interact with CD95 expressed on the glioma
cells, we showed that LN-308 and LN-319 cells sensitized to
CD95L-induced apoptosis by CD95 gene transfer [20] were
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Fig. 1. Expression of APO2L receptors in human malignant glioma
cell lines. A: DR4, DR5, DcR1 and DcR2 expression were analyzed
by RT-PCR as outlined in Section 2. RNA quality was ascertained
by parallel actin ampli¢cation (3, water control; P, cDNA plasmid
control). The ampli¢ed fragment sizes were 217 bp for DR4, 152 bp
for DR5, 140 bp for DcR1 and 200 bp for DcR1. B: CD95 expres-
sion was determined by £ow cytometry. The SFI correponds to the
ratio of £uoresence obtained with CD95 antibody versus isotype
control antibody [20].
Fig. 2. APO2L-induced apoptosis of human malignant glioma cells:
comparison with CD95L. The cells were exposed to CD95L at 10
(+) or 100 (++) U/ml, to APO2L at 0.1 (+) or 1 (++) Wg/ml, or
combinations of CD95L (10 U/ml) plus APO2L (0.1 Wg/ml) or of
CD95L (100 U/ml) plus APO2L (1 Wg/ml), in the absence (open
bars) or presence (¢lled bars) of cycloheximide (10 Wg/ml) for 16 h.
Survival was asssessed by crystal violet staining. Data are expressed
as mean percentages of survival and S.D. (n = 3).
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not sensitized to APO2L-induced apoptosis (data not shown).
3.3. Genetic modulation of APO2L-induced apoptosis in
human glioma cells
Next, we characterized the subcellular pathway of APO2L-
induced apoptosis in glioma cells (Table 1). Similar to
CD95L-induced apoptosis [16,21], APO2L-induced cell death
was attenuated by ectopic expression of bcl-2. Since caspase
activation is an important step in CD95-mediated apoptosis in
non-glial cells, we generated glioma cell sublines expressing
the viral caspase inhibitor, crm-A. Both CD95L- and
APO2L-induced apoptosis were completely blocked by crm-
A. The essential requirement of caspase activity for apoptosis
was con¢rmed by pharmacological experiments using the
pseudosubstrate peptide inhibitor, DEVD-cho which com-
pletely blocked APO2L-induced cell death at 400 WM (data
not shown).
We have previously reported that CD95L-induced glioma
cell apoptosis is attenuated by dexamethasone and the lipoxy-
genase inhibitor, NDGA [1,22]. A similar degree of protection
from apoptosis was observed when APO2L was used as a
death stimulus even though dexamethasone-mediated protec-
tion failed to reach signi¢cance in LN-229 cells (Fig. 3C^F).
Of the 12 human glioma cell lines, four retain wild-type p53
activity (LN-229, U87MG, D247MG, U138MG) whereas
eight are mutant or deleted for p53 [23]. Fig. 2 indicates
that the p53 status has no impact on the sensitivity to
APO2L or CD95L. Since DR5 expression is up-regulated by
wild-type p53 in non-glial cells [24], we examined APO2L-
induced apoptosis in LN-18 and LN-229 cells which were
transfected with temperature-sensitive p53 Val135 which is mu-
tant at 38.5‡C and assumes wild-type conformation at 32.5‡C
[17]. Table 1 shows that the ectopic expression of mutant
(38.5‡C) p53 does not signi¢cantly alter CD95L- or APO2L-
induced apoptosis in the absence of CHX. In the presence of
CHX, p53-transfected cells are moderately more sensitive to
apoptosis induced by both death ligands. Wild-type p53 en-
hances apoptosis induced by both ligands both in the absence
and presence of CHX. However, these e¡ects are small and of
questionable biological signi¢cance.
4. Discussion
Human malignant gliomas are rather resistant to current
therapeutic approaches which include cytoreductive surgery,
irradiation, and adjuvant chemotherapy. However, these cells
are not resistant to CD95L-induced apoptosis which is there-
fore a promising experimental strategy to eliminate human
glioma cells in vivo [2]. The major problem with CD95 target-
ing in vivo is not lack of e⁄cacy but serious concerns about
potential toxicity [14]. Given the complex regulation of the
APO2L/APO2L receptor system with regard to di¡erential
expression of agonistic and inhibitory receptors, we examined
whether the APO2L system might be more suitable for the
experimental therapy of gliomas in vivo than the CD95/
CD95L system. Expression of DR4 in the normal brain has
not been examined whereas DR5, DcR1 and DcR2 expression
was not detected by Northern blotting in normal brain [6,7].
We ¢nd that most human glioma cell lines express either
DR4 or DR5, or both, agonistic APO2L receptors whereas
few cell lines express the antagonistic receptors DcR1 and
DcR2 (Fig. 1). Further, 10 of 12 cell lines are rather suscep-
tible to APO2L-induced apoptosis, notably in the presence of
CHX (Fig. 2). There was considerable overlap between the
sensitivity or resistance patterns of the glioma cell lines to
APO2L and CD95L. The biochemical pathways of apoptosis
activated by both death ligands were very similar: bcl-2 and
caspase inhibitors were protective, as were dexamethasone
and the lipoxygenase inhibitor NDGA (Table 1, Fig. 3). Fur-
ther, sensitivity to both death ligands showed no dependence
on p53 genetic status, and ectopic expression of wild-type p53
moderately enhanced the cytotoxic e¡ects of both ligands,
consistent with p53-mediated induction of DR5 expression
in non-glial cells [24]. Thus, the death cascades triggered by
CD95 and DR4/DR5 converge early and are likely to be iden-
tical downstream. A defect in the death domain-induced sig-
nalling cascade might be responsible for the resistance of two
cell lines, U138MG and U373MG. Given the more complex
regulation of APO2L receptors, with death-inhibitory recep-
tors expressed preferentially by non-neoplastic cells, APO2L
targeting may be an equally e¡ective but safer approach of
targeting therapeutic apoptosis to human malignant glioma
cells.
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Fig. 3. Death ligand-induced DNA fragmentation in human malig-
nant glioma cells and cytoprotective e¡ects of dexamethasone and
NDGA. A, B: LN-229 cells were treated with CD95L (100 U/ml,
A, left) or APO2L (1 Wg/ml, B, right) in the absence or presence of
CHX (10 Wg/ml) for 4, 8 or 16 h (open circles, death ligand alone;
open squares, CHX alone; ¢lled triangles, death ligand plus CHX).
Data are expressed as mean percentages of DNA fragmentation
(n = 3, S.E.M.6 10%). C^F: LN-229 (C, E) or T98G cells (D, F)
were exposed to CD95L (100 U/ml) or APO2L (1 Wg/ml) in the ab-
sence (open bars) or presence (¢lled bars) of NDGA (20 WM) (C,
D) or dexamethasone (100 nM) (DEX, E, F). Data are expressed as
mean percentages and S.E.M. of survival assessed by crystal violet
staining (n = 3, *P6 0.05, t-test).
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